- Report
- October 2023
- 80 Pages
United Kingdom
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
South Korea
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
Saudi Arabia
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
India
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
Germany
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
France
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- October 2023
- 80 Pages
China
From €662EUR$750USD£574GBP
€1324EUR$1,500USD£1,148GBP
- Report
- November 2023
- 147 Pages
Asia Pacific
From €1324EUR$1,500USD£1,148GBP
- Report
- November 2023
- 146 Pages
Africa, Middle East
From €1324EUR$1,500USD£1,148GBP
- Report
- November 2023
- 146 Pages
Europe
From €1324EUR$1,500USD£1,148GBP
- Report
- November 2023
- 127 Pages
North America
From €1324EUR$1,500USD£1,148GBP
- Report
- November 2023
- 337 Pages
Global
From €3179EUR$3,600USD£2,755GBP
- Report
- March 2022
- 71 Pages
Asia Pacific
From €1324EUR$1,500USD£1,148GBP
- Report
- March 2022
- 157 Pages
Global
From €3179EUR$3,600USD£2,755GBP
- Report
- March 2025
- 50 Pages
Kenya
From €530EUR$600USD£459GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €530EUR$600USD£459GBP
- Report
- March 2025
- 50 Pages
Egypt
From €530EUR$600USD£459GBP
From €530EUR$600USD£459GBP
- Report
- March 2025
- 50 Pages
Greece
From €530EUR$600USD£459GBP

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders.
Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists.
Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more